{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:05:24Z","timestamp":1790827524331,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40257-021-00666-9","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T10:03:27Z","timestamp":1642500207000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["New Developments in Topical Acne Therapy"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-6246","authenticated-orcid":false,"given":"Lara","family":"Drake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8008","authenticated-orcid":false,"given":"Sophia","family":"Reyes-Hadsall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-4102","authenticated-orcid":false,"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"issue":"1","key":"666_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5694\/mja16.00516","volume":"206","author":"AJ Cooper","year":"2017","unstructured":"Cooper AJ, Harris VR. Modern management of acne. Med J Aust. 2017;206(1):41\u20135. https:\/\/doi.org\/10.5694\/mja16.00516.","journal-title":"Med J Aust"},{"issue":"5","key":"666_CR2","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73.e33. https:\/\/doi.org\/10.1016\/j.jaad.2015.12.037.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"666_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/j.1610-0387.2007.06274.x","volume":"5","author":"K Degitz","year":"2007","unstructured":"Degitz K, Placzek M, Borelli C, Plewig G. Pathophysiology of acne. JDDG J der Deutschen Dermatologischen Gesellschaft. 2007;5(4):316\u201323.","journal-title":"JDDG J der Deutschen Dermatologischen Gesellschaft."},{"issue":"2 Suppl","key":"666_CR4","first-page":"4","volume":"76","author":"GF Webster","year":"2005","unstructured":"Webster GF. The pathophysiology of acne. Cutis. 2005;76(2 Suppl):4\u20137.","journal-title":"Cutis"},{"issue":"3","key":"666_CR5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/bjd.12149","volume":"168","author":"K Bhate","year":"2013","unstructured":"Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474\u201385.","journal-title":"Br J Dermatol"},{"issue":"4","key":"666_CR6","first-page":"577","volume":"41","author":"V Goulden","year":"1999","unstructured":"Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41(4):577\u201380.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"666_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamadermatol.2020.0464","volume":"156","author":"JS Barbieri","year":"2020","unstructured":"Barbieri JS. A new class of topical acne treatment addressing the hormonal pathogenesis of acne. JAMA Dermatol. 2020;156(6):619\u201320. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0464.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"666_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s13555-020-00481-w","volume":"11","author":"JJ Han","year":"2021","unstructured":"Han JJ, Faletsky A, Barbieri JS, Mostaghimi A. New acne therapies and updates on use of spironolactone and isotretinoin: a narrative review. Dermatology and Therapy. 2021;11(1):79\u201391. https:\/\/doi.org\/10.1007\/s13555-020-00481-w.","journal-title":"Dermatology and Therapy."},{"key":"666_CR9","unstructured":"Retin-A-Tretinoin Cream, Retin-A-Tretinoin Gel Drug Label Information DailyMed. 2019. https:\/\/dailymed-nlm-nih-gov.ezproxy.library.tufts.edu\/dailymed\/drugInfo.cfm?setid=9556d73d-c573-4e0a-9feb-764ce2d1107b."},{"key":"666_CR10","unstructured":"Retin-A Micro-Tretinoin Gel DailyMed. 2017. https:\/\/dailymed-nlm-nih-gov.ezproxy.library.tufts.edu\/dailymed\/drugInfo.cfm?setid=08ab7e0c-1437-455f-815c-98904d96a289."},{"key":"666_CR11","unstructured":"Retin-A (Tretinoin) Cream Gel Liquid for Topical Use Only FDA Access Data. 2002. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/16921s21s22s25lbl.pdf."},{"issue":"1","key":"666_CR12","first-page":"41","volume":"4","author":"JB Bikowski","year":"2005","unstructured":"Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4(1):41\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"10","key":"666_CR13","first-page":"1084","volume":"17","author":"SK Tyring","year":"2018","unstructured":"Tyring SK, Kircik LH, Pariser DM, Guenin E, Bhatt V, Pillai R. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris: assessment of efficacy and safety in patients aged 9 years and older. J Drugs Dermatol. 2018;17(10):1084\u201391.","journal-title":"J Drugs Dermatol"},{"key":"666_CR14","unstructured":"Tazorac (tazarotene) gel, 0.05% and 0.1%, for topical use FDA Access Data. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020600s010lbl.pdf."},{"issue":"1","key":"666_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.36849\/jdd.2020.3977","volume":"19","author":"EA Tanghetti","year":"2020","unstructured":"Tanghetti EA, Werschler WP, Lain T, Guenin E, Martin G, Pillai R. Tazarotene 0.045% lotion for once-daily treatment of moderate-to-severe acne vulgaris: results from two phase 3 trials. J Drugs Dermatol. 2020;19(1):70\u20137. https:\/\/doi.org\/10.36849\/jdd.2020.3977.","journal-title":"J Drugs Dermatol"},{"key":"666_CR16","unstructured":"Shari L. Targum M, MPH, FACP, FACC. NDA 211882: NDA Approval accessdata.fda.gov: FDA U.S. Food & Drug Administration; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2019\/211882Orig1s000ltr.pdf."},{"issue":"6","key":"666_CR17","first-page":"542","volume":"18","author":"EA Tanghetti","year":"2019","unstructured":"Tanghetti EA, Kircik LH, Green LJ, Guenin E, Harris S, Martin G, et al. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a novel tazarotene 0.045% lotion and tazarotene 0.1% cream in the treatment of moderate-to-severe acne vulgaris. J Drugs Dermatol. 2019;18(6):542.","journal-title":"J Drugs Dermatol"},{"key":"666_CR18","unstructured":"FDA approves Differin Gel 0.1% for over-the-counter use to treat acne: first retinoid approved for over-the-counter use FDA New Release: FDA.gov; 2016. https:\/\/www-fda-gov.ezproxy.library.tufts.edu\/news-events\/press-announcements\/fda-approves-differin-gel-01-over-counter-use-treat-acne."},{"issue":"2","key":"666_CR19","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/bjd.16719","volume":"179","author":"J Aubert","year":"2018","unstructured":"Aubert J, Piwnica D, Bertino B, Blanchet-R\u00e9thor\u00e9 S, Carlavan I, D\u00e9ret S, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-\u03b3 agonist trifarotene. Br J Dermatol. 2018;179(2):442\u201356. https:\/\/doi.org\/10.1111\/bjd.16719.","journal-title":"Br J Dermatol"},{"issue":"1","key":"666_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jdv.15794","volume":"34","author":"U Blume-Peytavi","year":"2020","unstructured":"Blume-Peytavi U, Fowler J, Kem\u00e9ny L, Draelos Z, Cook-Bolden F, Dirschka T, et al. Long-term safety and efficacy of trifarotene 50 \u03bcg\/g cream, a first-in-class RAR-\u03b3 selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166\u201373. https:\/\/doi.org\/10.1111\/jdv.15794.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"666_CR21","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jaad.2019.02.044","volume":"80","author":"J Tan","year":"2019","unstructured":"Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 \u03bcg\/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.044.","journal-title":"J Am Acad Dermatol"},{"key":"666_CR22","unstructured":"Azelex (Allergan) (azelaic acid cream) 20% FDA Access Data. 2003. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20428slr016_azelex_lbl.pdf."},{"issue":"1","key":"666_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2018.08.020","volume":"80","author":"LS Gold","year":"2019","unstructured":"Gold LS, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart IA. A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: results of 2 randomized, double-blind, phase 3 studies. J Am Acad Dermatol. 2019;80(1):168\u201377. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.020.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"666_CR24","doi-asserted-by":"publisher","first-page":"CD011154","DOI":"10.1002\/14651858I011154.pub2","volume":"3","author":"Z Yang","year":"2020","unstructured":"Yang Z, Zhang Y, Lazic Mosler E, Hu J, Li H, Zhang Y, et al. Topical benzoyl peroxide for acne. Cochrane Database Syst Rev. 2020;3(3):CD011154. https:\/\/doi.org\/10.1002\/14651858I011154.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"666_CR25","unstructured":"Sol-Gel Technologies Announces FDA Approval of TWYNEO Globe News Wire. 2021. https:\/\/www.globenewswire.com\/news-release\/2021\/07\/27\/2269561\/0\/en\/Sol-Gel-Technologies-Announces-FDA-Approval-of-TWYNEO.html."},{"key":"666_CR26","unstructured":"Del Rosso J, Sugarman, J., Levy-Hachman, O., Mizrahi, R. TWYNEO (Microencapsulated benzoyl peroxide 3%, tretinoin 0.1%) phase 3 efficacy and safety: results from two randomized controlled clinical trials. Sol-Gel Technologies. https:\/\/ir.sol-gel.com\/static-files\/c1d4a3ff-e56d-4abf-932b-53337d8961b3."},{"issue":"6","key":"666_CR27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2020.0465","volume":"156","author":"A Hebert","year":"2020","unstructured":"Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621\u201330. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0465.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"666_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1365-2133.2011.10332.x","volume":"165","author":"V Trifu","year":"2011","unstructured":"Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17\u03b1-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol. 2011;165(1):177\u201383. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10332.x.","journal-title":"Br J Dermatol"},{"issue":"2","key":"666_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4161\/derm.1.2.8472","volume":"1","author":"M Picardo","year":"2009","unstructured":"Picardo M, Ottaviani M, Camera E, Mastrofrancesco A. Sebaceous gland lipids. Dermatoendocrinol. 2009;1(2):68\u201371. https:\/\/doi.org\/10.4161\/derm.1.2.8472.","journal-title":"Dermatoendocrinol."},{"issue":"1","key":"666_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jdermsci.2011.04.001","volume":"63","author":"M Eisinger","year":"2011","unstructured":"Eisinger M, Li WH, Anthonavage M, Pappas A, Zhang L, Rossetti D, et al. A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011;63(1):23\u201332. https:\/\/doi.org\/10.1016\/j.jdermsci.2011.04.001.","journal-title":"J Dermatol Sci"},{"key":"666_CR31","unstructured":"Botanix Progresses Development Plan for BTX 1503: BiotechDispatch; 2020. https:\/\/biotechdispatch.com.au\/news\/botanix-progresses-development-plan-for-btx-1503."},{"issue":"8","key":"666_CR32","first-page":"12","volume":"9","author":"H Baldwin","year":"2016","unstructured":"Baldwin H, Blanco D, McKeever C, Paz N, Vasquez YN, Quiring J, et al. Results of a phase 2 efficacy and safety study with SB204, an investigational topical nitric oxide-releasing drug for the treatment of acne vulgaris. J Clin Aesthet Dermatol. 2016;9(8):12\u20138.","journal-title":"J Clin Aesthet Dermatol."},{"key":"666_CR33","unstructured":"AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure: First-in-Class Therapy Designed to Deliver Nitric Oxide for Application in Diverse Inflammatory Conditions: AOBiome Therapeutics; 2017. https:\/\/www.aobiome.com\/pressreleases\/aobiome-completes-patient-enrollment-in-phase-2-clinical-trial-of-lead-candidate-b244-to-treat-elevated-blood-pressure\/."},{"key":"666_CR34","unstructured":"Our Product Pipeline. Botanix Pharmaceuticals. https:\/\/botanixpharma.com\/pipeline\/."},{"issue":"2","key":"666_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40268-020-00299-z","volume":"20","author":"R Batra","year":"2020","unstructured":"Batra R, Sadhasivam S, Saini S, Gupta S, Bisen RKS, Sinha M, et al. Efficacy and safety of VB-1953 topical gel in non-responder acne patients with clindamycin-resistant cutibacterium acnes. Drugs R&D. 2020;20(2):95\u2013104. https:\/\/doi.org\/10.1007\/s40268-020-00299-z.","journal-title":"Drugs R&D"},{"key":"666_CR36","unstructured":"Information NCfB. PubChem Compound Summary for CID 16131446, Omiganan pentahydrochloride. 2021. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Omiganan-pentahydrochloride."},{"key":"666_CR37","doi-asserted-by":"crossref","unstructured":"Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, et al. Efficacy and safety of a fixed-dose clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: a randomized phase II study of the first triple-combination drug. Am J Clin Dermatol. 2021.","DOI":"10.1007\/s40257-021-00650-3"},{"key":"666_CR38","unstructured":"Drug Profile: Tazarotene topical. Dr Reddys Laboratories Adis Insight: Springer; 2020. https:\/\/adisinsight.springer.com\/drugs\/800044869."},{"key":"666_CR39","unstructured":"Weller M. Minocycline, adapalene combination foam shows good results in acne treatment: Healio; 2021. https:\/\/www.healio.com\/news\/dermatology\/20210128\/minocycline-adapalene-combination-foam-shows-good-results-in-acne-treatment."},{"issue":"1","key":"666_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5114\/ada.2019.82825","volume":"36","author":"W Bara\u0144ska-Rybak","year":"2019","unstructured":"Bara\u0144ska-Rybak W, Kowalska-Ol\u0119dzka E. New indications for topical ivermectin 1% cream: a case series study. Postepy dermatologii I alergologii. 2019;36(1):58\u201362. https:\/\/doi.org\/10.5114\/ada.2019.82825.","journal-title":"Postepy dermatologii I alergologii."},{"key":"666_CR41","unstructured":"Bioequivalence study of clindamycin phosphate topical lotion, 1% in subjects with acne vulgaris. ClinicalTrials.gov Identifier: NCT03717506 ClinicalTrials.gov. 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03717506?view=results."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00666-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-021-00666-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-021-00666-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T10:20:58Z","timestamp":1646907658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-021-00666-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["666"],"URL":"https:\/\/doi.org\/10.1007\/s40257-021-00666-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"assertion":[{"value":"6 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lara Drake, Sophia Reyes-Hadsall, and John S Barbieri have no conflicts of interest that are directly relevant to the content of this article. Dr. Mostaghimi has received royalty payments from Pfizer for licensing of the ALTO tool; has participated in clinical trials related to alopecia by Incyte, Lilly, Concert, and Aclaris; and has received consulting fees from Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"All authors contributed to the study conception and design. Lara Drake and Sophia Reyes-Hadsall conducted the literature search and data analysis and wrote the first draft of the manuscript. All authors commented on subsequent versions of the manuscript and read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}